newsfilter
← Latest News
PR Newswire·

Liminal BioSciences Reports Second Quarter 2022 Financial Results and Business Highlights

$55.8M of cash and cash equivalents at June 30, 2022 Discontinuation of fezagepras development Net loss from continuing operations of $6.5 million during the quarter ended June 30, 2022 compared to $12.6 million during the quarter ended June 30, 2021